Skip to main content
SpringerLink
Log in

Indications

  • Chapter
Pratique de la défibrillation cardiaque implantable

  • 311 Accesses

Résumé

Il existe deux grands types d’indication à l’implantation d’un défibrillateur implantable: les indications de prévention secondaire (le patient a présenté une arythmie ventriculaire soutenue grave documentée ou une mort subite réanimée) et les indications de prévention primaire (le patient va très bien mais il appartient à une population à haut risque de mort subite).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Aliot E, Chauvin M, Daubert JC et al (2006) Indications du défibrillateur automatique implantable: rapport du groupe de rythmologie de la Société Française de Cardiologie. Arch Mal Coeur Vaiss 99:141–54

    PubMed  CAS  Google Scholar 

  2. (1997) The antiarrhythmics versus implantable defibrillators (AVID Investigators). A comparison of antiarrhythmic-drug therapy with implantable defibrillator in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337:1576–83

    Google Scholar 

  3. Connolly SJ, Gent M, Roberts RS et al (2000) Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101:1297–302

    PubMed  CAS  Google Scholar 

  4. Bokhari F, Newman D, Greene M et al (2004) Long-term comparison of the implantable cardioverter defibrillator versus amiodarone eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation 110:112–6

    Article  PubMed  CAS  Google Scholar 

  5. Kuck KH, Cappato R, Sibels J et al (2000) Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The Cardiac Arrest Study Hamburg (CASH). Circulation 102:748–54

    PubMed  CAS  Google Scholar 

  6. Connolly SJ, Hallstrom AP, Cappato R et al (2000) Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmic vs implantable defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 21:2071–8

    Article  PubMed  CAS  Google Scholar 

  7. MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001–7

    Article  Google Scholar 

  8. Moss AJ, Hall WJ, Cannom DS et al (1996) Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators. (MADIT) N Engl J Med 335:33–40

    Google Scholar 

  9. Buxton AE, Lee KL, Fisher JD et al (1999) Randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. (MUSST) N Engl J Med 341:1882–90

    Article  CAS  Google Scholar 

  10. Bigger JT Jr (1997) Prophylactic use of implanted cardiac defibrillators in patients at with risk for ventricular arrhythmias after coronary-artery by pass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 337:1569–75

    Article  PubMed  Google Scholar 

  11. Moss AJ, Zareba W, Hall WJ et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction (MADIT II). N Engl J Med 346:877–83

    Article  PubMed  Google Scholar 

  12. Hohnloser SH, Kuck KH, Dorian P (2004) On behalf of the DINAMIT investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351:2481–8

    Article  PubMed  CAS  Google Scholar 

  13. Bänsch D, Antz M, Boczor S et al (2002) Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy (CAT). Circulation 105:1453–8

    Article  PubMed  Google Scholar 

  14. Strickberger SA, Hummel JD, Bartlett TG et al (2003) Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia AMIOVIRT. JACC 41:1707–12

    PubMed  Google Scholar 

  15. Kadish A, Dyer A, Daubert JP et al (2004) For the defibrillators in non-ischemic cardiomyopathy treatment evaluation (DEFINITE) investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350:2151–8

    Article  PubMed  CAS  Google Scholar 

  16. Bardy GH, Lee KL, Mark DB et al (2005) Sudden Cardiac Death in Heart Failure Trial (SCDHeFT) investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225–37

    Article  PubMed  CAS  Google Scholar 

  17. Cazeau S, Leclercq C, Lavergne T et al (2001) Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay (MUSTIC). N Engl J Med 344:873–80

    Article  PubMed  CAS  Google Scholar 

  18. Abraham WT, Fisher WG, Smith AL et al (2002) Cardiac resynchronization in chronic heart failure. The MIRACLE prospective study. N Engl J Med 346:1845–53

    Article  PubMed  Google Scholar 

  19. Gras D, Leclercq C, Tang AS et al (2002) Cardiac resynchronization therapy in advanced heart failure; The multicenter InSync clinical study. Eur J Heart Fail 4:311–20

    Article  PubMed  Google Scholar 

  20. Higgins SL, Hummel JD, Niazi IK et al (2003) (CONTAK-CD) cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 42:1454–9

    Article  PubMed  Google Scholar 

  21. Bristow MR, Saxon LA, Boehmer J et al (2004) Comparison of medical therapy, pacing, and defibrillation in heart failure (COMPANION) investigators. Cardiacresynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140–50

    Article  PubMed  CAS  Google Scholar 

  22. Cleland JGF, Daubert JC, Erdmann E et al (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure (CARE-HF). N Engl J Med 352:1539–49

    Article  PubMed  CAS  Google Scholar 

  23. Linde C, Abraham WT, Gold MR et al (2008) Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 52:1834–43

    Article  PubMed  Google Scholar 

  24. St John Sutton M, Ghio S, Plappert T et al (2009) Cardiac resynchronization induces major structural and functional reverse remodeling in patients with NYHA class I/II heart failure. Circulation 120:1858–65

    Article  PubMed  Google Scholar 

  25. Moss AJ, Hall WJ, Cannom DS et al (2009) Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events. MADIT-CRT Study. N Engl J Med 361:1329–38

    Article  PubMed  Google Scholar 

  26. Dickstein K, Vardas PE, Auricchio A et al (2010) Focused Update of ESC guidelines on device therapy in heart failure An update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Europace 12:1526–36

    Article  PubMed  Google Scholar 

  27. Maron BJ, Cecchi F, McKenna WJ (1994) Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy. Br Heart J 72:S13–S18

    Article  PubMed  CAS  Google Scholar 

  28. Cecchi F, Olivotto I, Montereggi A et al (1995) Hypertrophic cardiomyopathy in Tuscani: clinical course and outcome in an unselected regional population. J Am Coll cardiol 26:1529–36

    Article  PubMed  CAS  Google Scholar 

  29. Kofflard MJ, Ten Cate NJ, Van Der Lee C, Van Domburg RT (2003) Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identifiation of risk factors for sudden cardiac death and clinical deterioration. J Am Coll cardiol 6:981–6

    Google Scholar 

  30. Elliot PM, Poloniecki J, Dickie S et al (2000) Sudden death in hypertrophic cardiomyopathy identification of high risk patients. J Am Coll Cardiol 7:2212–8

    Article  Google Scholar 

  31. Priori SG, Aliot E, Blomstrom-Lundqvist C et al (2002) Task force on sudden cardiac death. European Society of Cardiology. Europace 4:3–18

    Article  PubMed  CAS  Google Scholar 

  32. Maron BJ, Estes III NAM, Maron MS et al (2003) Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy 107:2872–5

    Google Scholar 

  33. Maron BJ, Olivotto I, Spirito P et al (2000) Epidemiology of hypertrophic cardiomyopathy-related death. Circulation 102:858–64

    PubMed  CAS  Google Scholar 

  34. Maron BJ, McKenna WJ, Danielson GK et al (2003) ACC/ESC clinical experts consensus document on hypertrophic cardiomyopathy. Eur Heart J 24:1965–91

    Article  PubMed  Google Scholar 

  35. Maron BJ, Shen WK, Link MS et al (2000) Efficacy of implantable cardioverterdefibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 342:365–73

    Article  PubMed  CAS  Google Scholar 

  36. Behr ER, Elliot P, McKenna WJ (2002) Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy. Cardiac Electrophysiology Review 6:482–6

    Article  PubMed  Google Scholar 

  37. McKenna WJ, Behr ER (2002) Hypertrophic cardiomyopathy: management, risk stratification, prevention of sudden death. Heart 87:169–76

    Article  PubMed  Google Scholar 

  38. Sen-Chowdhry S, Lowe MD, Sporton SC (2004) Arrhythmogenic right ventricular cardiomyopathy: clinical presentation, diagnosis and management. Am J Med 117:685–95

    Article  PubMed  Google Scholar 

  39. Nasir K, Bomma C, Tandri H et al (2004) Electrocardiographic Features of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy According to Disease Severity. A Need to Broaden Diagnostic Criteria. Circulation 110:1527–34

    Article  PubMed  Google Scholar 

  40. Fontaine G, Tonet J, Gallais Y et al (2000) Ventricular tachycardia catheter ablation in arrhythmogenic right ventricular dysplasia. A 16-year experience. Curr Cardiol Reports 2:498–506

    Article  CAS  Google Scholar 

  41. Chang CE, Roden DM (2000) The long QT syndrome: genetic basis and clinical implications. J Am Coll Cardiol 36:1–12

    Article  Google Scholar 

  42. Zareba W, Moss AJ, Schwartz PJ et al (1998) Influence of the genotype on the clinical course of the long-QT syndrome. N Engl J Med 339:960–6

    Article  PubMed  CAS  Google Scholar 

  43. Priori SG, Schwartz PJ, Napolitano C et al (2003) Risk stratification in the long QT syndrome. N Engl J Med 348:1866–74

    Article  PubMed  Google Scholar 

  44. Moss AJ, Zareba W, Benhorin J et al (1995) ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 92:2929–34

    PubMed  CAS  Google Scholar 

  45. Schwartz PJ, Spazzolini C, Priori SG et al (2010) Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them? Data from the european long-QT syndrome implantable cardioverter-defibrillator (LQTS-ICD) registry. Circulation 122:1272–82

    Article  PubMed  Google Scholar 

  46. Brugada P, Brugada J (1992) Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report. J Am Coll Cardiol 20:1391–6

    Article  PubMed  CAS  Google Scholar 

  47. Naccarelli GV, Antzelevitch C (2001) The Brugada syndrome: clinical, genetic, cellular, and molecular abnormalities. Am J Med 110:573–81

    Article  PubMed  CAS  Google Scholar 

  48. Chen Q, Kirsch GE, Zhang D et al (1998) Genetic basis and molecular mechanisms for idiopathic ventricular fibrillation. Nature 392:293–6

    Article  PubMed  CAS  Google Scholar 

  49. Lukas A, Antzelevitch C (1996) Phase 2 reentry as a mechanisme of initiation of circus movement reentry in canine epicardium exposed to simulated ischemia: the antiarrhythmic effects of 4-aminopyridine. Cardiovasc Res 32:593–603

    PubMed  CAS  Google Scholar 

  50. Antzelevitch C, Yan GX (2000) Cellular and ionic mechanisms responsible for the Brugada syndrome. J Electrocardiol 33:33–9

    Article  PubMed  Google Scholar 

  51. Wilde AA, Antzelevitch C, Borggrefe M et al (2002) Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation 106:2514–9

    Article  PubMed  Google Scholar 

  52. Hermida JS, Lemoine JL, Aoun FB et al (2000) Prevalence of the Brugada syndrome in an apparently healthy population. Am J Cardiol 86:91–4

    Article  PubMed  CAS  Google Scholar 

  53. Brugada R, Brugada J, Antzelevitch C (2000) Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 101:510–5

    PubMed  CAS  Google Scholar 

  54. Brugada J, Brugada R, Antzelevitch C et al (2002) Longterm follow-up of individuals with the electrocardiographic pattern of right bundle branch block and ST-elevation in precordial leads V1 to V3. Circulation 105:73–78

    Article  PubMed  Google Scholar 

  55. Priori S, Napolitano C, Gasparini M et al (2002) Natural history of Brugada syndrome. Circulation 105:1342–7

    Article  PubMed  Google Scholar 

  56. Probst V, Veltmann C, Eckardt L et al (2010) Long-term prognosis of patients diagnosed with Brugada syndrome: Results from teh FINGER Brugada syndrome registry. Circulation 121:635–43

    Article  PubMed  CAS  Google Scholar 

  57. Eckardt L, Kirchhof P, Schulze-Bahr E et al (2002) Electrophysiologic investigation in Brugada syndrome; yield of programmed ventricular stimulation at two ventricular sites with up to three premature beats. Eur Heart J 23:1394–401

    Article  PubMed  CAS  Google Scholar 

  58. Brugada J, Antzelevitch C, Borggrefe M et al (2005) Brugada Syndrome: Report of the Second Consensus Conference. Circulation 111:659–70

    Article  PubMed  Google Scholar 

  59. Hermida JS, Denjoy I, Clerc J et al (2004) Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 43:1853–60

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hôpital Haut-Lévêque, Avenue Magellan, 33604, Pessac, France

    Pierre Bordachar & Philippe Ritter

  2. Clinique Saint-Augustin, Service de cardiologie, 114, Avenue d’Ares, 33000, Bordeaux, France

    Stéphane Garrigue & Sylvain Reuter

  3. Knappschaftskrankenhaus, D-82380, Peissenberg, Allemagne

    Wilhelm Fischer

Authors
  1. Pierre Bordachar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wilhelm Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stéphane Garrigue
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sylvain Reuter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Philippe Ritter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag France

About this chapter

Cite this chapter

Bordachar, P., Fischer, W., Garrigue, S., Reuter, S., Ritter, P. (2012). Indications. In: Pratique de la défibrillation cardiaque implantable. Springer, Paris. https://doi.org/10.1007/978-2-8178-0283-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0283-1_2

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0282-4

  • Online ISBN: 978-2-8178-0283-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation